Compare Li Auto Inc (LI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Sana Biotechnology Inc — how do they compare? Li Auto Inc trades at $12.48 (market cap $12.28B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Li Auto Inc is far larger — about 10.9× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| LI | SANA | |
|---|---|---|
Market Cap | $12.28B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.69 | $5.92 |
52-Week Low | $11.74 | $2.68 |
Enterprise Value | $1.11B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $12.49, down 2.73% on the day, amid a bearish technical signal and mixed earnings performance. The company reported a net income margin of -1.66% for 2025, with revenue declining to $112.31 billion from $144.5 billion in 2024, while launching new SUV models like the Li L6 in July 2026 to boost deliveries. Analyst consensus is a 'Buy' with a $14.80 price target, but negative cash flow and competitive pressures in China's EV market pose challenges.
Outlook remains cautious due to profitability concerns and volatile cash flows, with near-term risks from domestic competition and global expansion hurdles. The stock offers potential upside if execution improves, but investors should monitor delivery trends and margin recovery amid industry headwinds.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
